{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Steroid+treatment&page=7", "query": { "intervention": "Steroid treatment", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 4082, "total_pages": 409, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Steroid+treatment&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Steroid+treatment&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T20:54:24.145Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00064337", "title": "S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Plasma Cell Myeloma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 104, "start_date": "2004-01", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2018-08-09", "last_synced_at": "2026-10-09T20:54:24.145Z", "location_count": 35, "location_summary": "Little Rock, Arkansas • Sacramento, California • Boise, Idaho + 19 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Boise", "state": "Idaho" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Salina", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00064337" }, { "nct_id": "NCT00184041", "title": "Intensified Post Remission Therapy Containing PEG-Asparaginase", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 47, "start_date": "2004-07", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2014-05-22", "last_synced_at": "2026-10-09T20:54:24.145Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00184041" }, { "nct_id": "NCT04092673", "title": "Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "eFT226", "type": "DRUG" }, { "name": "Sotorasib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Effector Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2019-10-25", "completion_date": "2025-03-31", "has_results": false, "last_update_posted_date": "2024-05-21", "last_synced_at": "2026-10-09T20:54:24.145Z", "location_count": 14, "location_summary": "Los Angeles, California • Newport Beach, California • Palo Alto, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04092673" }, { "nct_id": "NCT00003541", "title": "Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "CHOP regimen", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "1998-06", "completion_date": "2006-07", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-10-09T20:54:24.145Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003541" }, { "nct_id": "NCT05333029", "title": "Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease" ], "interventions": [ { "name": "Allogeneic mesenchymal stromal cells (MSCs)", "type": "BIOLOGICAL" }, { "name": "Extracorporeal photopheresis (ECP)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Molly Gallogly", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2024-10-01", "completion_date": "2025-06-01", "has_results": false, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-10-09T20:54:24.145Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05333029" }, { "nct_id": "NCT03710772", "title": "Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 51, "start_date": "2019-05-01", "completion_date": "2027-03-22", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-09T20:54:24.145Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03710772" }, { "nct_id": "NCT02224729", "title": "Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma" ], "interventions": [ { "name": "Bendamustine hydrochloride", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2014-08-25", "completion_date": "2018-11-17", "has_results": true, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-10-09T20:54:24.145Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02224729" }, { "nct_id": "NCT06016465", "title": "Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs?", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Dexamethasone Oral", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Texas Tech University Health Sciences Center, El Paso", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 84, "start_date": "2023-09-15", "completion_date": "2028-01-30", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-09T20:54:24.145Z", "location_count": 1, "location_summary": "El Paso, Texas", "locations": [ { "city": "El Paso", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06016465" }, { "nct_id": "NCT03815019", "title": "iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Feeding Behavior", "Feeding Disorder of Infancy or Early Childhood" ], "interventions": [ { "name": "Megestrol Acetate", "type": "DRUG" }, { "name": "iKanEat Behavioral Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "9 Months", "maximum_age": "108 Months", "sex": "ALL", "summary": "9 Months to 108 Months" }, "enrollment_count": 70, "start_date": "2019-08-15", "completion_date": "2025-03-19", "has_results": true, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-10-09T20:54:24.145Z", "location_count": 8, "location_summary": "San Diego, California • Orlando, Florida • Indianapolis, Indiana + 5 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03815019" }, { "nct_id": "NCT01881412", "title": "Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "fluticasone", "type": "DRUG" }, { "name": "Standard Asthma Discharge Instructions", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Rhode Island Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "3 Years to 12 Years" }, "enrollment_count": 118, "start_date": "2012-08", "completion_date": "2018-04", "has_results": true, "last_update_posted_date": "2020-05-18", "last_synced_at": "2026-10-09T20:54:24.145Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT01881412" } ] }